APACHE-4: Evaluation of Three Strategies Based on Vaginal Self-sampling Kit Send to Home of Unscreened Women for Cervical Cancer

Sponsor
University Hospital, Tours (Other)
Overall Status
Completed
CT.gov ID
NCT03856684
Collaborator
Centre Régional de Coordination des Dépistages des Cancers - Centre-Val de Loire (Other), Centre d'Investigation Clinique-P1415, TOURS (Other)
10,400
1
4
20.3
513

Study Details

Study Description

Brief Summary

Despite the existence of an effective screening test (pap smear), cervical cancer is, every year in France, the cause of more than 3,000 new cases and 1,100 deaths. But, in France, 4 in 10 women are not screened or not often enough (nearly 7 millions women). It is therefore necessary to develop new strategies to reach these women. The etiological factor of this cancer is persistent infection with High-Risk Human PapillomaVirus (HR-HPV). Thereby, HPV-based tests could be alternative screening tests. Vaginal self-sampling with HR-HPV test is simpler and less intrusive than the pap smear. It has been shown that sending vaginal self-sampling kit (with HPV test) to unscreened women's home is a powerful means to increase the participation rate of cervical cancer screening. It seems interesting to explore methods to increase the efficiency of this strategy by optimizing the ratio of the number of kits used compared to the number of kits sent. Two approaches will be tested: a system "available on request" of the kit and / or the addition of an SMS (Short Message Service) reminder.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Self-sampling kit sent at home
  • Behavioral: Self-sampling kit sent at home + SMS reminder
  • Behavioral: Letter offering a self-sampling kit "on request"+ SMS reminder
  • Behavioral: SMS offering a self-sampling kit "on request"+ SMS reminder
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
10400 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Randomized Trial Evaluating Women's Behavior Not Participating in Cervical Cancer Screening Facing Three Strategies for Optimizing Home Sending by Post of Vaginal Self-sampling Kit
Actual Study Start Date :
Feb 11, 2020
Actual Primary Completion Date :
Jul 14, 2021
Actual Study Completion Date :
Oct 20, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Self-sampling kit sent at home

Sending of a vaginal self-sampling kit at home

Behavioral: Self-sampling kit sent at home
Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Experimental: Self-sampling kit sent at home + SMS reminder

Sending of a vaginal self-sampling kit at home + a SMS reminder is sent if the woman do not (in 2 months) : perform a pap smear or send her vaginal self-sample to the laboratory or contact the screening center to inform to an exclusion reason

Behavioral: Self-sampling kit sent at home + SMS reminder
Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear. After 2 months without "return", a SMS reminder about the available self-sampling kit is sent to the woman. We call "return" : the receipt of the vaginal self-sample at the laboratory the performance of a pap smear Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Experimental: Letter offering a self-sampling kit "on request"+ SMS reminder

Sending of letter offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us. If they do ask for the kit, one kit is sending to their home. For these women, a SMS reminder is sent if the woman do not (in 2 months) : perform a pap smear or send her vaginal self-sample to the laboratory or contact the screening center to inform to an exclusion reason

Behavioral: Letter offering a self-sampling kit "on request"+ SMS reminder
Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (kit provided on request) or to perform a pap smear. Women are invited to ask the kit online, on our website. For the women who ask the kit, after 2 months without "return", a SMS reminder about the available self-sampling kit is sent to the woman. We call "return" : the receipt of the vaginal self-sample at the laboratory the performance of a pap smear Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Experimental: SMS offering a self-sampling kit "on request"+ SMS reminder

Sending of SMS offering a vaginal self-sampling kit. Women can ask for this kit on line, on our website or by calling us. If they do ask for the kit, one kit is sending to their home. For these women, a SMS reminder is sent if the woman do not (in 2 months) : perform a pap smear or send her vaginal self-sample to the laboratory or contact the screening center to inform to an exclusion reason

Behavioral: SMS offering a self-sampling kit "on request"+ SMS reminder
Selected women receive a SMS inviting them to ask a vaginal self sampling kit to perform a sample at home and send it to a laboratory (kit provided on request). Women are invited to ask the kit by answering "1" by SMS. For the women who ask the kit, after 2 months without "return", a SMS reminder about the available self-sampling kit is sent to the woman. We call "return" : the receipt of the vaginal self-sample at the laboratory the performance of a pap smear Information about recent screening test or a cervical screening exclusion reason When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory.

Outcome Measures

Primary Outcome Measures

  1. Participation / no participation to complete cervical cancer screening [9 months after postal mail (with or without the kit) or SMS]

    Complete cervical cancer screening is defined as one of the followings : perform a pap smear perform a vaginal self-sampling with negative HR-HPV test perform a vaginal self-sampling with noninterpretable HR-HPV test result followed by a control pap smear (nine-month extension to do the pap smear after the sending of the HPV result) perform a vaginal self-sampling with positive HR-HPV test result followed by a control pap smear (nine-month extension to do the pap smear after the sending of the HPV result)

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 66 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • women from 30 to 66 years old

  • women living in french territorial division 37 ("Indre-et-Loire")

  • women with a mobile phone in database

  • women who do not perform a pap smear in the last 4 years

  • women who do not answer to a first "invitation" letter to perform a pap smear

Exclusion Criteria:
  • STOP SMS

  • HPV cervical pathology during treatment

  • Hysterectomy including cervix

Contacts and Locations

Locations

Site City State Country Postal Code
1 Crcdc-Cvl Tours France 37044

Sponsors and Collaborators

  • University Hospital, Tours
  • Centre Régional de Coordination des Dépistages des Cancers - Centre-Val de Loire
  • Centre d'Investigation Clinique-P1415, TOURS

Investigators

  • Principal Investigator: Julie BOYARD, MSc, University Hospital of TOURS

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Tours
ClinicalTrials.gov Identifier:
NCT03856684
Other Study ID Numbers:
  • DR170135-APACHE-4
First Posted:
Feb 27, 2019
Last Update Posted:
Oct 29, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Tours
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 29, 2021